Atara Biotherapeutics (NASDAQ:ATRA) Receives Daily News Sentiment Score of 0.11
Media headlines about Atara Biotherapeutics (NASDAQ:ATRA) have been trending somewhat positive on Thursday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Atara Biotherapeutics earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the company’s share price in the near term.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Atara Biotherapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference (finance.yahoo.com)
- Atara Biotherapeutics Announces Two Presentations at MSParis2017, Including Updated, Interim Results from a Phase 1 Study of Autologous ATA188 in Patients with Progressive Multiple Sclerosis (MS) (finance.yahoo.com)
- Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Scheduled to Post Quarterly Earnings on Monday (americanbankingnews.com)
- Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Expected to Announce Earnings of -$0.91 Per Share (americanbankingnews.com)
ATRA has been the subject of several analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $47.00 price objective on shares of Atara Biotherapeutics in a research note on Friday, April 21st. Zacks Investment Research cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. Jefferies Group LLC reiterated a “buy” rating and issued a $30.00 price objective on shares of Atara Biotherapeutics in a research note on Thursday, June 22nd. William Blair reiterated an “outperform” rating on shares of Atara Biotherapeutics in a research note on Monday, June 26th. Finally, ValuEngine lowered shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $25.75.
Atara Biotherapeutics (NASDAQ:ATRA) traded up 1.02% during trading on Thursday, reaching $14.90. 143,817 shares of the company’s stock traded hands. The company’s 50 day moving average is $14.69 and its 200-day moving average is $15.88. Atara Biotherapeutics has a 52-week low of $11.80 and a 52-week high of $25.73. The stock’s market cap is $433.72 million.
In other news, CFO John Mcgrath sold 4,000 shares of the stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $15.11, for a total value of $60,440.00. Following the sale, the chief financial officer now directly owns 113,762 shares of the company’s stock, valued at $1,718,943.82. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Christopher Haqq sold 6,000 shares of the stock in a transaction dated Thursday, June 15th. The stock was sold at an average price of $12.65, for a total transaction of $75,900.00. Following the completion of the sale, the executive vice president now directly owns 368,080 shares in the company, valued at $4,656,212. The disclosure for this sale can be found here. Over the last three months, insiders sold 54,308 shares of company stock worth $797,382. Insiders own 16.10% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/03/atara-biotherapeutics-nasdaqatra-earns-daily-coverage-optimism-rating-of-0-11-updated-updated-updated.html.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.